• PI 3-kinase p110α Polyclonal Antibody
1 1

Upingbio

YP-Ab-14913-100UL

PI 3-kinase p110α Polyclonal Antibody

PI 3-kinase p110α Polyclonal Antibody

$0.00 USD
$0.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
  • Gene Name: PIK3CA
  • Immunogen: The antiserum was produced against synthesized peptide derived from human PI 3-kinase p110alpha. AA range:470-519
  • Specificity: PI 3-kinase p110α Polyclonal Antibody detects endogenous levels of PI 3-kinase p110α protein.
  • Composition: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
  • Source: Polyclonal, Rabbit,IgG
  • Dilution ratio: IF: 1:50-200 Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/40000. Not yet tested in other applications.
  • Purification process: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
  • Concentration: 1 mg/ml
  • Storage: -20°C/1 year
  • Other Names: PIK3CA; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit alpha isoform; PI3-kinase subunit alpha; PI3K-alpha; PI3Kalpha; PtdIns-3-kinase subunit alpha; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit
  • Background: Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016],
  • Function: catalytic activity:ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.,disease:Defects in PIK3CA are associated with breast cancer [MIM:114480].,disease:Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].,disease:Defects in PIK3CA are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases. These typical features relate to the biology of the disease, which is a principal determinant of outcome.,disease:Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550].,disease:PI3KCA mutations affecting exons 9 and 20 display gender-and tissue-specific patterns, thus suggesting that the
  • Species: Human;Mouse;Rat
  • Range: IF;WB;IHC;ELISA
  • Protein: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
  • DA: 110kD
View full details